Convalescent Plasma for Coronavirus Disease 2019: Dose is the Key

Overview

Journal J Transl Int Med

Publisher Sciendo

Specialty General Medicine

Date 2021 Sep 9

PMID 34497745

Citations 1

Authors

Jiangquan Yu

Ruiqiang Zheng

Haibo Qiu

Affiliations

Soon will be listed here.

Citing Articles

Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients.

Agrawal A, Jha T, Gogoi P, Diwaker P, Goel A, Khan A Transfus Apher Sci. 2022; 61(6):103455.

PMID: 35618641 PMC: 9090870. DOI: 10.1016/j.transci.2022.103455.

References

Hung I, To K, Lee C, Lee K, Chan K, Yan W . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4):447-56. PMC: 7531589. DOI: 10.1093/cid/ciq106. View

Valk S, Piechotta V, Chai K, Doree C, Monsef I, Wood E . Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev. 2020; 5:CD013600. PMC: 7271896. DOI: 10.1002/14651858.CD013600. View

Mair-Jenkins J, Saavedra-Campos M, Baillie J, Cleary P, Khaw F, Lim W . The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2014; 211(1):80-90. PMC: 4264590. DOI: 10.1093/infdis/jiu396. View

Zeng Q, Yu Z, Gou J, Li G, Ma S, Zhang G . Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. J Infect Dis. 2020; 222(1):38-43. PMC: 7197534. DOI: 10.1093/infdis/jiaa228. View

van Griensven J, Edwards T, de Lamballerie X, Semple M, Gallian P, Baize S . Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med. 2016; 374(1):33-42. PMC: 5856332. DOI: 10.1056/NEJMoa1511812. View

Perotti C, Del Fante C, Baldanti F, Franchini M, Percivalle E, Nepita E . Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol. Intern Emerg Med. 2020; 15(5):819-824. PMC: 8849045. DOI: 10.1007/s11739-020-02384-2. View

Salazar E, Christensen P, Graviss E, Nguyen D, Castillo B, Chen J . Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. Am J Pathol. 2020; 190(11):2290-2303. PMC: 7417901. DOI: 10.1016/j.ajpath.2020.08.001. View

Cao H, Shi Y . Convalescent plasma: possible therapy for novel coronavirus disease 2019. Transfusion. 2020; 60(5):1078-1083. PMC: 7267548. DOI: 10.1111/trf.15797. View

Pei S, Yuan X, Zhang Z, Yao R, Xie Y, Shen M . Convalescent plasma to treat COVID-19: clinical experience and efficacy. Aging (Albany NY). 2021; 13(6):7758-7766. PMC: 8034927. DOI: 10.18632/aging.202795. View

10.

Bloch E, Shoham S, Casadevall A, Sachais B, Shaz B, Winters J . Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6):2757-2765. PMC: 7259988. DOI: 10.1172/JCI138745. View

11.

Epstein J, Burnouf T . Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang. 2020; 115(6):485-487. PMC: 7264781. DOI: 10.1111/vox.12939. View

12.

Liu S, Lin H, Baine I, Wajnberg A, Gumprecht J, Rahman F . Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020; 26(11):1708-1713. DOI: 10.1038/s41591-020-1088-9. View

13.

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View

14.

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J . Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16):1582-1589. PMC: 7101507. DOI: 10.1001/jama.2020.4783. View

15.

Joyner M, Carter R, Senefeld J, Klassen S, Mills J, Johnson P . Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med. 2021; 384(11):1015-1027. PMC: 7821984. DOI: 10.1056/NEJMoa2031893. View

16.

Knudson C, Jackson J . COVID-19 convalescent plasma: phase 2. Transfusion. 2020; 60(6):1332-1333. PMC: 7267265. DOI: 10.1111/trf.15842. View

17.

Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F . Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020; 92(10):1890-1901. PMC: 7262027. DOI: 10.1002/jmv.25882. View

18.

Salazar E, Perez K, Ashraf M, Chen J, Castillo B, Christensen P . Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. Am J Pathol. 2020; 190(8):1680-1690. PMC: 7251400. DOI: 10.1016/j.ajpath.2020.05.014. View

19.

Mendoza R, Fyke W, Daniel D, Gabutan E, Das B, Bajaj H . Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes. Hum Immunol. 2021; 82(4):255-263. PMC: 7885628. DOI: 10.1016/j.humimm.2021.02.007. View

20.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J . Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020; 117(17):9490-9496. PMC: 7196837. DOI: 10.1073/pnas.2004168117. View